Edition:
United States

Vectura Group PLC (VEC.L)

VEC.L on London Stock Exchange

108.10GBp
12:01pm EDT
Change (% chg)

3.10 (+2.95%)
Prev Close
105.00
Open
105.10
Day's High
108.20
Day's Low
104.20
Volume
2,410,597
Avg. Vol
1,923,039
52-wk High
166.97
52-wk Low
88.90

Select another date:

Wed, Sep 6 2017

BRIEF-Vectura Group posts HY revenue of 78.8 million pounds

* HY REVENUE 78.8 MILLION POUNDS VERSUS 73.9 MILLION POUNDS A YEAR AGO

BRIEF-Vectura signs VR410 agreement with Pulmatrix

* PROGRESSING DEVELOPMENT OF BRANDED GENERIC TIOTROPIUM BROMIDE PROGRAMME (VR410) FOR US MARKET, ACCELERATED THROUGH LICENCE DEAL WITH PULMATRIX

BRIEF-Vectura announces ANDA filing for US generic version of Advair Diskus

* CONFIRMS STATEMENT MADE BY PARTNER HIKMA IN RESPECT OF ANDA FILING FOR A US GENERIC VERSION OF ADVAIR DISKUS SOURCE TEXT FOR EIKON: FURTHER COMPANY COVERAGE:

Vectura signs deal with Novartis for generic U.S. lung therapy

Vectura Group Plc said on Wednesday it has signed an exclusive deal with Sandoz AG, a unit of Swiss drugmaker Novartis, to develop a generic copy of an existing combined lung therapy for the U.S. market.

Vectura signs deal with Novartis for generic U.S. lung therapy

June 28 Vectura Group Plc said on Wednesday it has signed an exclusive deal with Sandoz AG, a unit of Swiss drugmaker Novartis, to develop a generic copy of an existing combined lung therapy for the U.S. market.

BRIEF-Vectura inks new U.S. deals for generic asthma therapy​

* ‍New development and licence agreement for a U.S. inhaled generic​

BRIEF-Vectura says to present positive phase I data for VR942

* Vectura group plc - vr942 positive phase i data to be presented at American Thoracic Society 113th Annual Conference

Select another date: